Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Rapamycin in Combination With Low-Dose Aracytin in Elderly Acute Myeloid Leukemia Patients (LAM-RAPA)

This study has been completed.
French Innovative Leukemia Organisation
Information provided by:
University Hospital, Toulouse Identifier:
First received: September 9, 2005
Last updated: June 19, 2008
Last verified: June 2008
These study is designed to evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin in elderly AML.

Condition Intervention Phase
Acute Myeloid Leukemia
Drug: rapamycin
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Rapamycin in Combination With Low-Dose Aracytin in Elderly Acute Myeloid Leukemia Patients. A Study From the Groupe Ouest Est d'étude Des Leucémies Aiguës Myéloïdes (GOELAMS)

Resource links provided by NLM:

Further study details as provided by University Hospital, Toulouse:

Primary Outcome Measures:
  • response rate

Secondary Outcome Measures:
  • tolerability
  • bioclinical markers of response

Enrollment: 50
Study Start Date: June 2005
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: rapamycin
    Other Name: RAPAMUNE
Detailed Description:
Evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin

Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age > 60 y.
  • Informed consent
  • de novo or secondary LAM(CML excluded) not elligible for intensive chemotherapy.
  • Previously untreated

Exclusion Criteria:

  • Renal impairment (serum creatinin >2N)
  • Hepatic impairment (TGO ou TGP > 5N), une cholestase (Phosphatases Alcalines or gamma-GT > 5N),bilirubin > 3N

    • Blast crisis CML
    • Acute Promyelocytic Leukemia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00235560

Service d'Hématologie, CHU
Angers, France, 49100
Service d'Hématologie, Hôpital Jean Minjoz
BESANçON, France, 25000
Service d'Hématologie CHU Purpan
Toulouse, France, 31059
Sponsors and Collaborators
University Hospital, Toulouse
French Innovative Leukemia Organisation
Principal Investigator: RECHER Christian CHU Toulouse
  More Information

Responsible Party: LLAU Marie-Elise, University Hospital Toulouse Identifier: NCT00235560     History of Changes
Other Study ID Numbers: 0402008
Study First Received: September 9, 2005
Last Updated: June 19, 2008

Keywords provided by University Hospital, Toulouse:
Elderly patients not eligible for intensive chemotherapy

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on May 25, 2017